NTT Biopharma PIPELINE

Platform Technologies

Brain Delivery Ocular Delivery (Eyedrop Nanoformulation) Nucleic Acid Delivery Oral Peptide Delivery Active Targeting Nanoparticle

Brain Disease

NTT-001 DNA Plasmid (IV Injection for PD)

Cancer Therapy

NTT-002

Ocular Disease

NTT-003 (Eyedrop Formulation for Wet-AMD) ASO (Eyedrop Formulation for Wet-AMD) Therapeutic Peptide (Eyedrop Formulation for Dry-AMD)

Active Targeting Nanoparticle

Active Targeting MSN Offers an Alternative to ADCs with Additional Advantages

• MSN can raise the drug-to-antibody ratio, diversifying the drug selection.

• MSN can use lower-potency APIs to lessen off-target effects.

• MSN can streamline ADC design, eliminating complex linker needs.